Moreover, as rosuvastatin and atorvastatin are more potent inhibitors of HMG-CoA reductase than simvastatin [62], this suggests that the effect observed on prostate cancer cells is not primarily mediated by a reduction of the synthesis of Coenzyme Q10 (Complex III of the mitochondrial electron transport chain). Here, HMGCR is linked to prostate carcinoma.